imagabalin

Small moleculeexperimental

Imagabalin was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development. — Wikipedia

Clinical trial activity

14 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Nov 1, 2005 (NCT00921063)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Jan 1, 2007
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Voltage-gated calcium channelMODULATOR
Voltage-gated calcium channel modulator
Ligand for the voltage-gated calcium channel alpha-2-delta subunit.

Chemistry & pharmacology

Loading structure…

SMILES

CCC[C@@H](C)C[C@H](N)CC(=O)O

Mol. weight: 173.26 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaImagabalin ↗
ChEMBLCHEMBL2103836 ↗

Also known as

imagabalin
imagabalin
imagabalin
pd 0332334
pd 0332334
pd-0332334
pd-0332334
pd-0332334
pf-00195889
pf-00195889

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00820794	Phase 1	May 1, 2009	Pfizer
NCT00738738	Phase 3	Jan 1, 2009	Pfizer
NCT00809536	Phase 1	Jan 1, 2009	Pfizer
NCT00800280	Phase 1	Jan 1, 2009	Pfizer
NCT00836069	Phase 3	Oct 1, 2008	Cedars-Sinai Medical Center, Pfizer
NCT00735267	Phase 3	Oct 1, 2008	Pfizer
NCT00730145	Phase 1	Sep 1, 2008	Pfizer
NCT00721422	Phase 1	Aug 1, 2008	Pfizer
NCT00658762	Phase 3	May 1, 2008	Pfizer
NCT00658372	Phase 3	May 1, 2008	Pfizer
NCT00658008	Phase 3	Apr 1, 2008	Pfizer
NCT00542685	Phase 3	Oct 1, 2007	Pfizer
NCT00537615	Phase 1	Sep 1, 2007	Pfizer
NCT00921063	Phase 2	Nov 1, 2005	Pfizer

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	14	13	3	2005
Cedars-Sinai Medical Center	Academic/Hospital	1	1	1	2008

2 organizations

Page 1 / 1